Stealthy Ganymed gets €45m for 'ideal' Mabs in tricky solid tumors
This article was originally published in Scrip
Executive Summary
The €45m that 80-person stealth company Ganymed Pharmaceuticals raised on 18 November from existing investors should take its lead compound through to the brink of Phase III completion in gastroesophageal cancer, but the company may still be looking to raise more money in order to leverage its compounds into US and Asia market. Ganymed, which had raised over €100m prior to this move, has been developing what it calls 'ideal' antibody products, those where the target is distributed widely on tumors but absent, or virtually absent from normal tissue.